Practical considerations: Growth hormone peptide protocols require months for musculoskeletal benefits versus weeks for direct-acting peptides (BPC-157, TB-500)
The publication by Ng et al
In some aspects, the at least one symptom is selected from the group consisting of: impaired or abnormal gait, neuronal oxidative stress, dementia, tremor, impaired balance, weakness, and personality changes
It is not intended for medical, veterinary, or therapeutic use
5-7 The importance of assessing the effect of PsA on HRQOL from a patient perspective has been acknowledged by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) working group, as evidenced by the inclusion of pain and fatigue in the PsA Core Domain Set